Skip to Main Content Skip to Site Map Skip to Accessibility Statement

EXCALIBER

April 25, 2024
Trial EXCALIBER
Cancer Type Haematological Cancers and Myeloma
Hospital(s) Belfast City Hospital
Information

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)